tiprankstipranks
Monopar Therapeutics Achieves Milestone in Cancer Treatment
Company Announcements

Monopar Therapeutics Achieves Milestone in Cancer Treatment

Pick the best stocks and maximize your portfolio:

The latest update is out from Monopar Therapeutics Inc ( (MNPR) ).

Monopar Therapeutics Inc. has announced the first successful dosing of a patient with their novel therapeutic radiopharmaceutical, MNPR-101-Lu, designed to target aggressive cancers by combining an antibody with a radioisotope. The treatment was well-tolerated, with no serious adverse reactions, marking a promising step in their ongoing clinical trials aimed at addressing unmet medical needs in cancer therapy.

See more insights into MNPR stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyMonopar Therapeutics doses first patient with MNPR-101-Lu
TheFlyMonopar Therapeutics price target raised to $37 from $9 at JonesResearch
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App